The Food and Drug Administration granted early approval to Ariad Pharmaceuticals Inc.'s (Nasdaq: ARIA) chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia treatment Iclusig but the stock price plummeted $4.95 to close at $18.93.